Performance of the BioFire Blood Culture Identification 2 panel for the diagnosis of bloodstream infections.
| Autor: | Peri AM; University of Queensland Centre for Clinical Research, Herston, Brisbane City, QLD, 4029, Australia., Bauer MJ; University of Queensland Centre for Clinical Research, Herston, Brisbane City, QLD, 4029, Australia., Bergh H; Central Microbiology, Pathology Queensland, Royal Brisbane and Women's Hospital, Herston, Brisbane City, QLD, 4029, Australia., Butkiewicz D; University of Queensland Centre for Clinical Research, Herston, Brisbane City, QLD, 4029, Australia., Paterson DL; University of Queensland Centre for Clinical Research, Herston, Brisbane City, QLD, 4029, Australia.; Infectious Diseases Unit, Royal Brisbane and Women's Hospital, Herston, Brisbane City, QLD, 4029, Australia., Harris PN; University of Queensland Centre for Clinical Research, Herston, Brisbane City, QLD, 4029, Australia.; Central Microbiology, Pathology Queensland, Royal Brisbane and Women's Hospital, Herston, Brisbane City, QLD, 4029, Australia. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Heliyon [Heliyon] 2022 Jul 19; Vol. 8 (7), pp. e09983. Date of Electronic Publication: 2022 Jul 19 (Print Publication: 2022). |
| DOI: | 10.1016/j.heliyon.2022.e09983 |
| Abstrakt: | Background: Conventional blood cultures methods are associated with long turnaround times, preventing early treatment optimization in bloodstream infections. The BioFire Blood Culture Identification 2 (BCID2) Panel is a new multiplex PCR applied on positive blood cultures, reducing time to pathogen identification and resistant markers detection. Methods: We conducted a prospective observational study including positive blood cultures from Intensive Care Units and Emergency Departments and performed BCID2 in addition to conventional testing. Concordance between the two methods was assessed and BCID2 performance characteristics were evaluated. Resistance markers detected by BCID2 were confirmed by in-house PCR. Whole genome sequencing was performed in discordant cases. Results: Among 60 monomicrobial blood cultures, BCID2 correctly identified 55/56 (91.7%) on-panel pathogens, showing an overall concordance of 98%. In 4/60 cases BCID2 did not detect any target and these all grew BCID2 off-panel bacteria. Only one discordant case was found. Sensitivity and specificity for Gram-positive bacteria on monomicrobial samples were 100% (95% CI 85.8-100%) and 100% (95% CI 90.3-100%) respectively, while for Gram-negatives 100% (95% CI 87.7-100) and 96.9% (95% CI 83.8-99.9%), respectively. Among two polymicrobial blood cultures, full concordance was observed in one case only. BCID2 identified antimicrobial resistance genes in 6/62 samples, all confirmed by in-house PCR (3 mecA/C S. epidermidis , 3 bla Conclusions: BCID2 showed good agreement with conventional methods. Studies to assess its clinical impact are warranted. Competing Interests: The authors declare no conflict of interest. (© 2022 The Author(s).) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|